Fosamprenavir Versus Other Protease Inhibitors

PHASE3CompletedINTERVENTIONAL
Enrollment

314

Participants

Timeline

Start Date

December 14, 2004

Primary Completion Date

June 29, 2007

Study Completion Date

June 29, 2007

Conditions
Infection, Human Immunodeficiency Virus I
Interventions
DRUG

Fosamprenavir

Fosamprenavir

Trial Locations (52)

731

GSK Investigational Site, Ponce

10014

GSK Investigational Site, New York

10595

GSK Investigational Site, Valhalla

11212

GSK Investigational Site, Brooklyn

14604

GSK Investigational Site, Rochester

18103

GSK Investigational Site, Allentown

20037

GSK Investigational Site, Washington D.C.

23666

GSK Investigational Site, Hampton

28209

GSK Investigational Site, Charlotte

28211

GSK Investigational Site, Charlotte

30339

GSK Investigational Site, Atlanta

30912

GSK Investigational Site, Augusta

32206

GSK Investigational Site, Jacksonville

32804

GSK Investigational Site, Orlando

33136

GSK Investigational Site, Miami

33145

GSK Investigational Site, Fort Lauderdale

33306

GSK Investigational Site, Fort Lauderdale

33308

GSK Investigational Site, Fort Lauderdale

33317

GSK Investigational Site, Plantation

33408

GSK Investigational Site, West Palm Beach

33614

GSK Investigational Site, Tampa

33901

GSK Investigational Site, Fort Myers

37813

GSK Investigational Site, Morristown

39202

GSK Investigational Site, Jackson

40202

GSK Investigational Site, Louisville

40536

GSK Investigational Site, Lexington

44304

GSK Investigational Site, Akron

48202

GSK Investigational Site, Detroit

67214

GSK Investigational Site, Wichita

70115

GSK Investigational Site, New Orleans

70121

GSK Investigational Site, New Orleans

71103

GSK Investigational Site, Shreveport

73104

GSK Investigational Site, Oklahoma City

74129

GSK Investigational Site, Tulsa

75208

GSK Investigational Site, Dallas

75246

GSK Investigational Site, Dallas

75604

GSK Investigational Site, Longview

76104

GSK Investigational Site, Fort Worth

77027

GSK Investigational Site, Houston

77098

GSK Investigational Site, Houston

80220

GSK Investigational Site, Denver

80528

GSK Investigational Site, Fort Collins

90069

GSK Investigational Site, Los Angeles

90210

GSK Investigational Site, Beverly Hills

90803

GSK Investigational Site, Laguna Beach

90813

GSK Investigational Site, Long Beach

91356

GSK Investigational Site, Tarzana

93720

GSK Investigational Site, Fresno

50309-1426

GSK Investigational Site, Des Moines

08844

GSK Investigational Site, Hillsborough

08244

GSK Investigational Site, Somers Point

29206-4713

GSK Investigational Site, Columbia

Sponsors

Lead Sponsor

Collaborators (1)

All Listed Sponsors
collaborator

GlaxoSmithKline

INDUSTRY

lead

ViiV Healthcare

INDUSTRY

NCT00094523 - Fosamprenavir Versus Other Protease Inhibitors | Biotech Hunter | Biotech Hunter